Takeaway

• The 3-arm POSEIDON phase 3 trial found that tremelimumab (an anti-CTLA-4 monoclonal antibody) in combination with durvalumab and chemotherapy (T+D+CT) as first-line therapy for metastatic NSCLC significantly improved PFS and OS.
• D+CT significantly improved PFS but not OS.

Why this matters

• T is thought to work by a complementary mechanism...